Advertisement
Advertisement
STVN
Stevanato Group S.p.A.
13.59
USDSponsored
-0.59
-4.14%
Mar 26, 15:59 UTC -4
Closed
After-Market
13.60
0.00
+0.01%
STVN Earnings Reports
Positive Surprise Ratio
STVN beat 12 of 19 last estimates.
63%
Next Report
Date of Next Report
May 01, 2026
Estimate for Q1 26 (Revenue/ EPS)
$274.80M
/$0.10
Implied change from Q4 25 (Revenue/ EPS)
-20.69%
/-44.44%
Implied change from Q1 25 (Revenue/ EPS)
+7.09%
/--
Stevanato Group S.p.A. earnings per share and revenue
On Mar 04, 2026, STVN reported earnings of 0.18 USD per share (EPS) for Q4 25, beating the estimate of 0.17 USD, resulting in a 4.35% surprise. Revenue reached 346.50 million, compared to an expected 339.67 million, with a 2.01% difference. The market reacted with a +18.81% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of 0.10 USD, with revenue projected to reach 274.80 million USD, implying an decrease of -44.44% EPS, and decrease of -20.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
electroCore, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.34
Surprise
+18.15%
FAQ
What were Stevanato Group S.p.A.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Stevanato Group S.p.A. reported EPS of $0.18, beating estimates by 4.35%, and revenue of $346.50M, 2.01% above expectations.
How did the market react to Stevanato Group S.p.A.'s Q4 2025 earnings?
The stock price moved up 18.81%, changed from $14.73 before the earnings release to $17.50 the day after.
When is Stevanato Group S.p.A. expected to report next?
The next earning report is scheduled for May 01, 2026.
What are the forecasts for Stevanato Group S.p.A.'s next earnings report?
Based on 10
analysts, Stevanato Group S.p.A. is expected to report EPS of $0.10 and revenue of $274.80M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement